Clostridium Difficile Infection Clinical Trials

174 clinical trials for Clostridium Difficile Infection across international registries, including 19 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile — RECRUITING · NA
• Fecal Microbiota Transplant National Registry — RECRUITING
• Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients — RECRUITING · PHASE2
• Fecal Microbiota Transplantation for C Diff Infection — RECRUITING · NA
• Study on Clostridium Difficile Infection in Infants — RECRUITING
• Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) — RECRUITING · PHASE2
• Safety and Efficacy of Fecal Microbiota Transplantation — RECRUITING · NA
• AN ADAPTIVE BASKET TRIAL TO EVALUATE EFFICACY OF LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION IN MANAGEMENT OF IRRITABLE BOWEL SYNDROME-DIARRHEA PREDOMINANT OR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION — RECRUITING
• AN EXPLORATORY, OPEN-LABEL, OLIGO-CENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF INTRAVENOUS DNV3837 IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE INFECTION — RECRUITING
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRS3123 COMPARED WITH ORAL VANCOMYCIN IN ADULTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION — RECRUITING · PHASE2
• A PHASE 3 OPEN-LABEL CLINICAL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) IN SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION — RECRUITING · PHASE3
• A MULTI-CENTER, DOUBLE BLIND, RANDOMIZED STUDY COMPARING THE EFFICACY OF LYOPHILIZED STERILE FECAL FILTRATE TO LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION (FMT) IN THE MANAGEMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) — RECRUITING
• A PHASE I, OPEN-LABEL, SINGLE-CENTRE STUDY OF THE SAFETY AND EFFICACY OF MET-2 IN PATIENTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (CDI) — RECRUITING · PHASE1
• PROSPECTIVE, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION FOR TREATMENTOF RECURRENT C.DIFFICILE INFECTION — RECRUITING
• AN OPEN-LABEL SAFETY ASSESSMENT OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) FOR THE TREATMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION — RECRUITING
• A PHASE 2B, PARALLEL-GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF SYN-004 COMPARED TO PLACEBO FOR THE PREVENTION OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA IN PATIENTS WITH A DIAGNOSIS OF LOWER RESPIRATORY TRACT INFECTION — RECRUITING · PHASE2
• A PHASE 1B/2A, RANDOMIZED, MULTI-CENTER, OPEN-LABEL, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF ORAL SYN-004 ON THE PHARMACOKINETICS OF INTRAVENOUS CEFTRIAXONE IN HEALTHY ADULT SUBJECTS WITH A FUNCTIONING ILCOSTOMY — RECRUITING · PHASE1
• A PHASE 2B PROSPECTIVE. RANDOMIZED. DOUBLE-BLINDED. PLACEBO-CONTROLLED CLINICAL STUDY DEMONSTRATING THE EFFICACY AND SAFETY OF REBIOTIX RBX2660 (MICROBIOTA SUSPENSION) FOR THE TREATMENT OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION — RECRUITING · PHASE2
• "EFFICACY, IMMUNOGENICITY, AND SAFETY STUDY OF CLOSTRIDIUM DIFFICLE TOXOIS VACCINE IN SUBJECTS AT RISK FOR C. DIFFICILE INFECTION." — RECRUITING
• A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-179811 in subjects with Clostridium difficile infection (CDI) — TERMINATED · PHASE2
• A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile — NOT_YET_RECRUITING · PHASE1
• A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program — SUSPENDED
• Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients — COMPLETED · PHASE2
• High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology — COMPLETED · NA
• Fecal Microbiota Transplant — COMPLETED · PHASE4
• Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection — COMPLETED · PHASE3
• ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI — COMPLETED · PHASE2
• Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics — COMPLETED · PHASE1
• Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) — TERMINATED · PHASE2
• A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection — WITHDRAWN
• Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection — COMPLETED · PHASE2
• Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea — COMPLETED · PHASE3
• Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea — COMPLETED · PHASE3
• FQ Restriction for the Prevention of CDI — COMPLETED
• ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection — COMPLETED · PHASE2
• Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection — COMPLETED
• Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) — COMPLETED · PHASE4
• Fecal Transplantation for Primary Clostridium Difficile Infection — TERMINATED · PHASE3
• Screening to Prophylax Against Clostridium Difficile Infection - — COMPLETED · PHASE4
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) — COMPLETED · PHASE3
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) — COMPLETED · PHASE3
• A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infection — OTHER · NA
• Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI) — WITHDRAWN
• Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) — TERMINATED · PHASE2
• Natural History of Clostridioides Difficile Infection — OTHER
• The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. Difficile Infection — COMPLETED · NA
• Effect of Acid Suppression Medication on Pediatric Microbiome — TERMINATED · NA
• Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics — COMPLETED · PHASE4
• Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection — COMPLETED
• Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) — COMPLETED · PHASE3

Refine this search